Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., Stroes, E. S. G., Tsimikas, S., Witztum, J. L., , , Agarwal, A., Ballantyne, C., Baum, S., Bergeron, J., Bruckert, E., Burdick, R., Castro-Cabezas, M., Cervi, M., Corder, C., DuFour, R., Farrington, C. M., Francis, G., Galitz, L., Hamstead, S., Hemphill, L., Huffman, C., Issa, B., Julius, U., Kane, J., Krempf, M., Martin, S., Powell, J., Shultzaberger, R., Thompson, C., Thompson-Hargrave, L., Toth, P., Turner, T., Valero, R., Verges, B., Visseren, F. L. J., Vyas, P., & Yataco, A. (2021). efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet, 9(5), 264–275. http://access.bl.uk/ark:/81055/vdc_100127348308.0x000006